Recent advances in α-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease.

Molecular neurobiology

Volumn 47, Issue 2, 2013, Pages 525-536

  Guerrero, Erika ^a   Vasudevaraju, P ^b   Hegde, Muralidhar L ^b   Britton, G B ^b   Rao, K S ^b  

^a INSTITUTO DE INVESTIGACIONES CIENTÍFICAS Y SERVICIOS DE ALTA TECNOLOGÍA   (Panama)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA SYNUCLEIN; PROTEIN BINDING;

ANIMAL; CELL DEATH; GLYCOSYLATION; HUMAN; METABOLISM; PARKINSON DISEASE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN FOLDING; TOXICITY;

ALPHA-SYNUCLEIN; ANIMALS; CELL DEATH; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN FOLDING;

EID: 84885468645     PISSN: None     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-012-8328-z     Document Type: Review

References (92)

1. 1. Y Izumi T Kume A Akaike 2011 Regulation of dopaminergic neuronal death by endogenous dopamine and proteasome activity Yakugaku Zasshi 131 1 21 27 10.1248/yakushi.131.21 1:CAS:528:DC%2BC3MXht1Cju7vO 21212609 Izumi Y, Kume T, Akaike A (2011) Regulation of dopaminergic neuronal death by endogenous dopamine and proteasome activity. Yakugaku Zasshi 131(1):21–27
2. 2. D Heisters 2011 Parkinson’s: symptoms, treatments and research Br J Nurs 20 9 548 554 21647015 Heisters D (2011) Parkinson’s: symptoms, treatments and research. Br J Nurs 20(9):548–554
3. 3. JM Shulman PL Jager De MB Feany 2011 Parkinson’s disease: genetics and pathogenesis Annu Rev Pathol 6 193 222 10.1146/annurev-pathol-011110-130242 10.1146/annurev-pathol-011110-130242 1:CAS:528:DC%2BC3MXjtVWrsrg%3D 21034221 Shulman JM, De Jager PL, Feany MB (2011) Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol 6:193–222. doi: 10.1146/annurev-pathol-011110-130242
4. 4. ML Hegde P Vasudevaraju KJ Rao 2010 DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson’s disease Front Biosci 15 418 436 10.2741/3628 1:CAS:528:DC%2BC3cXovFamt7k%3D 20036828 Hegde ML, Vasudevaraju P, Rao KJ (2010) DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson’s disease. Front Biosci 15:418–436
5. 5. L Defebvre 2010 Parkinson’s disease: role of genetic and environment factors. Involvement in everyday clinical practice Rev Neurol (Paris) 166 10 764 769 10.1016/j.neurol.2010.07.014 10.1016/j.neurol.2010.07.014 1:STN:280:DC%2BC3cfkvFWltw%3D%3D Defebvre L (2010) Parkinson’s disease: role of genetic and environment factors. Involvement in everyday clinical practice. Rev Neurol (Paris) 166(10):764–769. doi: 10.1016/j.neurol.2010.07.014
6. 6. K Nuytemans J Theuns M Cruts C Broeckhoven Van 2010 Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update Hum Mutat 31 7 763 780 10.1002/humu.21277 10.1002/humu.21277 1:CAS:528:DC%2BC3cXpslagtL8%3D 20506312 Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31(7):763–780. doi: 10.1002/humu.21277
7. 7. I Martin VL Dawson TM Dawson 2010 The impact of genetic research on our understanding of Parkinson’s disease Prog Brain Res 183 21 41 10.1016/S0079-6123(10)83002-X 10.1016/S0079-6123(10)83002-X 1:CAS:528:DC%2BC3cXhtlGjs77M 20696313 Martin I, Dawson VL, Dawson TM (2010) The impact of genetic research on our understanding of Parkinson’s disease. Prog Brain Res 183:21–41. doi: 10.1016/S0079-6123(10)83002-X
8. 8. I Martin VL Dawson TM Dawson 2011 Recent advances in the genetics of Parkinson’s disease Annu Rev Genomics Hum Genet 12 301 325 10.1146/annurev-genom-082410-101440 10.1146/annurev-genom-082410-101440 1:CAS:528:DC%2BC3MXht1yksbvN 21639795 Martin I, Dawson VL, Dawson TM (2011) Recent advances in the genetics of Parkinson’s disease. Annu Rev Genomics Hum Genet 12:301–325. doi: 10.1146/annurev-genom-082410-101440
9. 9. Pagon RA, Bird TD, Dolan CR et al (eds) (1993) GeneReviews™ [Internet]. University of Washington, Seattle, WA. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1116/
10. 10. ML Hegde KS Jagannatha Rao 2003 Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson’s disease Arch Biochem Biophys 418 2 169 178 10.1016/j.abb.2003.08.015 1:CAS:528:DC%2BD3sXns1Kktrs%3D 14522588 Hegde ML, Jagannatha Rao KS (2003) Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson’s disease. Arch Biochem Biophys 418(2):169–178
11. 11. L Maroteaux JT Campanelli RH Scheller 1988 Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal J Neurosci 8 8 2804 2815 1:CAS:528:DyaL1MXhsVyqsbY%3D 3411354 Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8(8):2804–2815
12. 12. NM Bonini BI Giasson 2005 Snaring the function of alpha-synuclein Cell 123 3 359 361 10.1016/j.cell.2005.10.017 10.1016/j.cell.2005.10.017 1:CAS:528:DC%2BD2MXht1altLjI 16269324 Bonini NM, Giasson BI (2005) Snaring the function of alpha-synuclein. Cell 123(3):359–361. doi: 10.1016/j.cell.2005.10.017
13. 13. S Chandra G Gallardo R Fernandez-Chacon OM Schluter TC Sudhof 2005 Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration Cell 123 3 383 396 10.1016/j.cell.2005.09.028 10.1016/j.cell.2005.09.028 1:CAS:528:DC%2BD2MXht1altLnN 16269331 Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123(3):383–396. doi: 10.1016/j.cell.2005.09.028
14. 14. DE Cabin K Shimazu D Murphy NB Cole W Gottschalk KL McIlwain B Orrison A Chen CE Ellis R Paylor B Lu RL Nussbaum 2002 Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein J Neurosci 22 20 8797 8807 1:CAS:528:DC%2BD38XosV2juro%3D 12388586 Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22(20):8797–8807
15. 15. S Lykkebo PH Jensen 2002 Alpha-synuclein and presynaptic function: implications for Parkinson’s disease Neuromolecular Med 2 2 115 129 10.1385/NMM:2:2:115 10.1385/NMM:2:2:115 1:CAS:528:DC%2BD3sXhtF2ntbY%3D 12428807 Lykkebo S, Jensen PH (2002) Alpha-synuclein and presynaptic function: implications for Parkinson’s disease. Neuromolecular Med 2(2):115–129. doi: 10.1385/NMM:2:2:115
16. 16. A Abeliovich Y Schmitz I Farinas D Choi-Lundberg WH Ho PE Castillo N Shinsky JM Verdugo M Armanini A Ryan M Hynes H Phillips D Sulzer A Rosenthal 2000 Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system Neuron 25 1 239 252 10.1016/S0896-6273(00)80886-7 1:CAS:528:DC%2BD3cXhtVWrt74%3D 10707987 Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239–252
17. 17. FJ Lee F Liu ZB Pristupa HB Niznik 2001 Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis Faseb J 15 6 916 926 10.1096/fj.00-0334com 1:CAS:528:DC%2BD3MXivFOrt7g%3D 11292651 Lee FJ, Liu F, Pristupa ZB, Niznik HB (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Faseb J 15(6):916–926
18. 18. NB Cole DD Murphy T Grider S Rueter D Brasaemle RL Nussbaum 2002 Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein J Biol Chem 277 8 6344 6352 10.1074/jbc.M108414200 10.1074/jbc.M108414200 1:CAS:528:DC%2BD38XhvFyru7c%3D 11744721 Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, Nussbaum RL (2002) Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein. J Biol Chem 277(8):6344–6352. doi: 10.1074/jbc.M108414200
19. 19. PH Jensen MS Nielsen R Jakes CG Dotti M Goedert 1998 Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson’s disease mutation J Biol Chem 273 41 26292 26294 10.1074/jbc.273.41.26292 1:CAS:528:DyaK1cXmslajsbw%3D 9756856 Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson’s disease mutation. J Biol Chem 273(41):26292–26294
20. 20. RA Bodner DE Housman AG Kazantsev 2006 New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions Cell Cycle 5 14 1477 1480 10.4161/cc.5.14.2929 1:CAS:528:DC%2BD28XpvF2qs7Y%3D 16861893 Bodner RA, Housman DE, Kazantsev AG (2006) New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions. Cell Cycle 5(14):1477–1480
21. 21. AG Kazantsev AM Kolchinsky 2008 Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease Arch Neurol 65 12 1577 1581 10.1001/archneur.65.12.1577 10.1001/archneur.65.12.1577 19064744 Kazantsev AG, Kolchinsky AM (2008) Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch Neurol 65(12):1577–1581. doi: 10.1001/archneur.65.12.1577
22. 22. G Yamin VN Uversky AL Fink 2003 Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers FEBS Lett 542 1–3 147 152 10.1016/S0014-5793(03)00367-3 1:CAS:528:DC%2BD3sXjt1Ohtbc%3D 12729915 Yamin G, Uversky VN, Fink AL (2003) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett 542(1–3):147–152
23. 23. PK Auluck G Caraveo S Lindquist 2010 Alpha-synuclein: membrane interactions and toxicity in Parkinson’s disease Annu Rev Cell Dev Biol 26 211 233 10.1146/annurev.cellbio.042308.113313 10.1146/annurev.cellbio.042308.113313 1:CAS:528:DC%2BC3cXhsFCnur7F 20500090 Auluck PK, Caraveo G, Lindquist S (2010) Alpha-synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu Rev Cell Dev Biol 26:211–233. doi: 10.1146/annurev.cellbio.042308.113313
24. 24. VN Uversky J Li P Souillac IS Millett S Doniach R Jakes M Goedert AL Fink 2002 Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta-and gamma-synucleins J Biol Chem 277 14 11970 11978 10.1074/jbc.M109541200 10.1074/jbc.M109541200 1:CAS:528:DC%2BD38XivVektrw%3D 11812782 Uversky VN, Li J, Souillac P, Millett IS, Doniach S, Jakes R, Goedert M, Fink AL (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta-and gamma-synucleins. J Biol Chem 277(14):11970–11978. doi: 10.1074/jbc.M109541200
25. 25. BS Gadad GB Britton KS Rao 2011 Targeting oligomers in neurodegenerative disorders: lessons from alpha-synuclein, tau, and amyloid-beta peptide J Alzheimers Dis 24 Suppl 2 223 232 10.3233/JAD-2011-110182 1:CAS:528:DC%2BC3MXltFGrt74%3D 21460436 Gadad BS, Britton GB, Rao KS (2011) Targeting oligomers in neurodegenerative disorders: lessons from alpha-synuclein, tau, and amyloid-beta peptide. J Alzheimers Dis 24(Suppl 2):223–232. doi: 10.3233/JAD-2011-110182
26. 26. PH Weinreb W Zhen AW Poon KA Conway PT Lansbury Jr 1996 NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded Biochemistry 35 43 13709 13715 10.1021/bi961799n 10.1021/bi961799n 1:CAS:528:DyaK28XmtVOls7s%3D 8901511 Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr (1996) NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35(43):13709–13715. doi: 10.1021/bi961799n
27. 27. VN Uversky J Li AL Fink 2001 Evidence for a partially folded intermediate in alpha-synuclein fibril formation J Biol Chem 276 14 10737 10744 10.1074/jbc.M010907200 10.1074/jbc.M010907200 1:CAS:528:DC%2BD3MXjvFCqtLs%3D 11152691 Uversky VN, Li J, Fink AL (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276(14):10737–10744. doi: 10.1074/jbc.M010907200
28. 28. D Eliezer E Kutluay R Bussell Jr G Browne 2001 Conformational properties of alpha-synuclein in its free and lipid-associated states J Mol Biol 307 4 1061 1073 10.1006/jmbi.2001.4538 10.1006/jmbi.2001.4538 1:CAS:528:DC%2BD3MXitlOisrg%3D 11286556 Eliezer D, Kutluay E, Bussell R Jr, Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307(4):1061–1073. doi: 10.1006/jmbi.2001.4538
29. 29. VN Uversky 2003 A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders J Biomol Struct Dyn 21 2 211 234 10.1080/07391102.2003.10506918 1:CAS:528:DC%2BD3sXnvFOksL8%3D 12956606 Uversky VN (2003) A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn 21(2):211–234
30. 30. DR Brown 2010 Oligomeric alpha-synuclein and its role in neuronal death IUBMB Life 62 5 334 339 10.1002/iub.316 1:CAS:528:DC%2BC3cXkvFegtLc%3D 20209636 Brown DR (2010) Oligomeric alpha-synuclein and its role in neuronal death. IUBMB Life 62(5):334–339. doi: 10.1002/iub.316
31. 31. A Oueslati M Fournier HA Lashuel 2010 Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson’s disease pathogenesis and therapies Prog Brain Res 183 115 145 10.1016/S0079-6123(10)83007-9 10.1016/S0079-6123(10)83007-9 1:CAS:528:DC%2BC3cXhtlGjs77J 20696318 Oueslati A, Fournier M, Lashuel HA (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson’s disease pathogenesis and therapies. Prog Brain Res 183:115–145. doi: 10.1016/S0079-6123(10)83007-9
32. 32. VN Uversky 2007 Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation J Neurochem 103 1 17 37 10.1111/j.1471-4159.2007.04764.x 1:CAS:528:DC%2BD2sXhtF2qu7nM 17623039 Uversky VN (2007) Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 103(1):17–37. doi: 10.1111/j.1471-4159.2007.04764.x
33. 33. M Stefani 2010 Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity Febs J 277 22 4602 4613 10.1111/j.1742-4658.2010.07889.x 10.1111/j.1742-4658.2010.07889.x 1:CAS:528:DC%2BC3cXhsFSgtbrP 20977664 Stefani M (2010) Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. Febs J 277(22):4602–4613. doi: 10.1111/j.1742-4658.2010.07889.x
34. 34. BD Rooijen van MM Claessens V Subramaniam 2010 Membrane permeabilization by oligomeric alpha-synuclein: in search of the mechanism PLoS One 5 12 e14292 10.1371/journal.pone.0014292 10.1371/journal.pone.0014292 21179192 van Rooijen BD, Claessens MM, Subramaniam V (2010) Membrane permeabilization by oligomeric alpha-synuclein: in search of the mechanism. PLoS One 5(12):e14292. doi: 10.1371/journal.pone.0014292
35. 35. VN Uversky J Li AL Fink 2001 Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure J Biol Chem 276 47 44284 44296 10.1074/jbc.M105343200 10.1074/jbc.M105343200 1:CAS:528:DC%2BD3MXos12nurw%3D 11553618 Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J Biol Chem 276(47):44284–44296. doi: 10.1074/jbc.M105343200
36. 36. A Santner VN Uversky 2010 Metalloproteomics and metal toxicology of alpha-synuclein Metallomics 2 6 378 392 10.1039/b926659c 10.1039/b926659c 1:CAS:528:DC%2BC3cXovVGksL4%3D 21072383 Santner A, Uversky VN (2010) Metalloproteomics and metal toxicology of alpha-synuclein. Metallomics 2(6):378–392. doi: 10.1039/b926659c
37. 37. VB Gupta ML Hegde KS Rao 2006 Role of protein conformational dynamics and DNA integrity in relevance to neuronal cell death in neurodegeneration Curr Alzheimer Res 3 4 297 309 10.2174/156720506778249452 1:CAS:528:DC%2BD28Xos1Kjsrg%3D 17017861 Gupta VB, Hegde ML, Rao KS (2006) Role of protein conformational dynamics and DNA integrity in relevance to neuronal cell death in neurodegeneration. Curr Alzheimer Res 3(4):297–309
38. 38. ML Hegde KS Rao 2007 DNA induces folding in alpha-synuclein: understanding the mechanism using chaperone property of osmolytes Arch Biochem Biophys 464 1 57 69 10.1016/j.abb.2007.03.042 10.1016/j.abb.2007.03.042 1:CAS:528:DC%2BD2sXot1ymtLc%3D 17537399 Hegde ML, Rao KS (2007) DNA induces folding in alpha-synuclein: understanding the mechanism using chaperone property of osmolytes. Arch Biochem Biophys 464(1):57–69. doi: 10.1016/j.abb.2007.03.042
39. 39. T Bartels JG Choi DJ Selkoe 2011 Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation Nature 477 7362 107 110 10.1038/nature10324 10.1038/nature10324 1:CAS:528:DC%2BC3MXhtFWku7nM 21841800 Bartels T, Choi JG, Selkoe DJ (2011) Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477(7362):107–110. doi: 10.1038/nature10324
40. 40. MH Polymeropoulos JJ Higgins LI Golbe WG Johnson SE Ide G Iorio Di G Sanges ES Stenroos LT Pho AA Schaffer AM Lazzarini RL Nussbaum RC Duvoisin 1996 Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23 Science 274 5290 1197 1199 10.1126/science.274.5290.1197 1:CAS:528:DyaK28XmvVyit74%3D 8895469 Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC (1996) Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science 274(5290):1197–1199
41. 41. LM Bekris IF Mata CP Zabetian 2010 The genetics of Parkinson disease J Geriatr Psychiatry Neurol 23 4 228 242 10.1177/0891988710383572 10.1177/0891988710383572 20938043 Bekris LM, Mata IF, Zabetian CP (2010) The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 23(4):228–242. doi: 10.1177/0891988710383572
42. 42. K Nuytemans B Meeus D Crosiers N Brouwers D Goossens S Engelborghs P Pals B Pickut M Broeck Van den E Corsmit P Cras PP Deyn De J Del-Favero C Broeckhoven Van J Theuns 2009 Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population Hum Mutat 30 7 1054 1061 10.1002/humu.21007 10.1002/humu.21007 1:CAS:528:DC%2BD1MXptlSjt7s%3D 19405094 Nuytemans K, Meeus B, Crosiers D, Brouwers N, Goossens D, Engelborghs S, Pals P, Pickut B, Van den Broeck M, Corsmit E, Cras P, De Deyn PP, Del-Favero J, Van Broeckhoven C, Theuns J (2009) Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Hum Mutat 30(7):1054–1061. doi: 10.1002/humu.21007
43. 43. K Nishioka OA Ross K Ishii JM Kachergus K Ishiwata M Kitagawa S Kono T Obi K Mizoguchi Y Inoue H Imai M Takanashi Y Mizuno MJ Farrer N Hattori 2009 Expanding the clinical phenotype of SNCA duplication carriers Mov Disord 24 12 1811 1819 10.1002/mds.22682 10.1002/mds.22682 19562770 Nishioka K, Ross OA, Ishii K, Kachergus JM, Ishiwata K, Kitagawa M, Kono S, Obi T, Mizoguchi K, Inoue Y, Imai H, Takanashi M, Mizuno Y, Farrer MJ, Hattori N (2009) Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 24(12):1811–1819. doi: 10.1002/mds.22682
44. 44. AL Biere SJ Wood J Wypych S Steavenson Y Jiang D Anafi FW Jacobsen MA Jarosinski GM Wu JC Louis F Martin LO Narhi M Citron 2000 Parkinson’s disease-associated alpha-synuclein is more fibrillogenic than beta-and gamma-synuclein and cannot cross-seed its homologs J Biol Chem 275 44 34574 34579 10.1074/jbc.M005514200 10.1074/jbc.M005514200 1:CAS:528:DC%2BD3cXotFWlt70%3D 10942772 Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu GM, Louis JC, Martin F, Narhi LO, Citron M (2000) Parkinson’s disease-associated alpha-synuclein is more fibrillogenic than beta-and gamma-synuclein and cannot cross-seed its homologs. J Biol Chem 275(44):34574–34579. doi: 10.1074/jbc.M005514200
45. 45. M Yonetani T Nonaka M Masuda Y Inukai T Oikawa S Hisanaga M Hasegawa 2009 Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant J Biol Chem 284 12 7940 7950 10.1074/jbc.M807482200 10.1074/jbc.M807482200 1:CAS:528:DC%2BD1MXjtVSmt7c%3D 19164293 Yonetani M, Nonaka T, Masuda M, Inukai Y, Oikawa T, Hisanaga S, Hasegawa M (2009) Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J Biol Chem 284(12):7940–7950. doi: 10.1074/jbc.M807482200
46. 46. CC Rospigliosi S McClendon AW Schmid TF Ramlall P Barre HA Lashuel D Eliezer 2009 E46K Parkinson’s-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein J Mol Biol 388 5 1022 1032 10.1016/j.jmb.2009.03.065 10.1016/j.jmb.2009.03.065 1:CAS:528:DC%2BD1MXltlCjs74%3D 19345692 Rospigliosi CC, McClendon S, Schmid AW, Ramlall TF, Barre P, Lashuel HA, Eliezer D (2009) E46K Parkinson’s-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. J Mol Biol 388(5):1022–1032. doi: 10.1016/j.jmb.2009.03.065
47. 47. A Puschmann OA Ross C Vilarino-Guell SJ Lincoln JM Kachergus SA Cobb SG Lindquist JE Nielsen ZK Wszolek M Farrer H Widner D Westen van D Hagerstrom K Markopoulou BA Chase K Nilsson J Reimer C Nilsson 2009 A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction Parkinsonism Relat Disord 15 9 627 632 10.1016/j.parkreldis.2009.06.007 10.1016/j.parkreldis.2009.06.007 19632874 Puschmann A, Ross OA, Vilarino-Guell C, Lincoln SJ, Kachergus JM, Cobb SA, Lindquist SG, Nielsen JE, Wszolek ZK, Farrer M, Widner H, van Westen D, Hagerstrom D, Markopoulou K, Chase BA, Nilsson K, Reimer J, Nilsson C (2009) A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord 15(9):627–632. doi: 10.1016/j.parkreldis.2009.06.007
48. 48. AW Michell RA Barker SK Raha R Raha-Chowdhury 2005 A case of late onset sporadic Parkinson’s disease with an A53T mutation in alpha-synuclein J Neurol Neurosurg Psychiatry 76 4 596 597 10.1136/jnnp. 2004.046425 10.1136/jnnp.2004.046425 1:STN:280:DC%2BD2M7ktlertg%3D%3D 15774457 Michell AW, Barker RA, Raha SK, Raha-Chowdhury R (2005) A case of late onset sporadic Parkinson’s disease with an A53T mutation in alpha-synuclein. J Neurol Neurosurg Psychiatry 76(4):596–597. doi: 10.1136/jnnp.2004.046425
49. 49. JJ Zarranz J Alegre JC Gomez-Esteban E Lezcano R Ros I Ampuero L Vidal J Hoenicka O Rodriguez B Atares V Llorens E Gomez Tortosa T Ser del DG Munoz JG Yebenes de 2004 The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann Neurol 55 2 164 173 10.1002/ana.10795 10.1002/ana.10795 1:CAS:528:DC%2BD2cXhs1Sgtb0%3D 14755719 Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55(2):164–173. doi: 10.1002/ana.10795
50. 50. S Grimm A Hoehn KJ Davies T Grune 2011 Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease Free Radic Res 45 1 73 88 10.3109/10715762.2010.512040 10.3109/10715762.2010.512040 1:CAS:528:DC%2BC3cXhsFGht7fF 20815785 Grimm S, Hoehn A, Davies KJ, Grune T (2011) Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease. Free Radic Res 45(1):73–88. doi: 10.3109/10715762.2010.512040
51. 51. KP Wu S Kim DA Fela J Baum 2008 Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation J Mol Biol 378 5 1104 1115 10.1016/j.jmb.2008.03.017 10.1016/j.jmb.2008.03.017 1:CAS:528:DC%2BD1cXlslWhs78%3D 18423664 Wu KP, Kim S, Fela DA, Baum J (2008) Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation. J Mol Biol 378(5):1104–1115. doi: 10.1016/j.jmb.2008.03.017
52. 52. JP Anderson DE Walker JM Goldstein R Laat de K Banducci RJ Caccavello R Barbour J Huang K Kling M Lee L Diep PS Keim X Shen T Chataway MG Schlossmacher P Seubert D Schenk S Sinha WP Gai TJ Chilcote 2006 Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease J Biol Chem 281 40 29739 29752 10.1074/jbc.M600933200 10.1074/jbc.M600933200 1:CAS:528:DC%2BD28XhtVahsb%2FI 16847063 Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281(40):29739–29752. doi: 10.1074/jbc.M600933200
53. 53. KE Paleologou A Oueslati G Shakked CC Rospigliosi HY Kim GR Lamberto CO Fernandez A Schmid F Chegini WP Gai D Chiappe M Moniatte BL Schneider P Aebischer D Eliezer M Zweckstetter E Masliah HA Lashuel 2010 Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions J Neurosci 30 9 3184 3198 10.1523/JNEUROSCI.5922-09.2010 10.1523/JNEUROSCI.5922-09.2010 1:CAS:528:DC%2BC3cXjtFahtLo%3D 20203178 Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, Chiappe D, Moniatte M, Schneider BL, Aebischer P, Eliezer D, Zweckstetter M, Masliah E, Lashuel HA (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30(9):3184–3198. doi: 10.1523/JNEUROSCI.5922-09.2010
54. 54. MK Mbefo KE Paleologou A Boucharaba A Oueslati H Schell M Fournier D Olschewski G Yin M Zweckstetter E Masliah PJ Kahle H Hirling HA Lashuel 2010 Phosphorylation of synucleins by members of the Polo-like kinase family J Biol Chem 285 4 2807 2822 10.1074/jbc.M109.081950 10.1074/jbc.M109.081950 1:CAS:528:DC%2BC3cXlvFCruw%3D%3D 19889641 Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, Kahle PJ, Hirling H, Lashuel HA (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 285(4):2807–2822. doi: 10.1074/jbc.M109.081950
55. 55. A Negro AM Brunati A Donella-Deana ML Massimino LA Pinna 2002 Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation Faseb J 16 2 210 212 10.1096/fj.01-0517fje 1:CAS:528:DC%2BD38XhsVeqt7g%3D 11744621 Negro A, Brunati AM, Donella-Deana A, Massimino ML, Pinna LA (2002) Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. Faseb J 16(2):210–212. doi: 10.1096/fj.01-0517fje
56. 56. M Neumann PJ Kahle BI Giasson L Ozmen E Borroni W Spooren V Muller S Odoy H Fujiwara M Hasegawa T Iwatsubo JQ Trojanowski HA Kretzschmar C Haass 2002 Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies J Clin Invest 110 10 1429 1439 10.1172/JCI15777 1:CAS:528:DC%2BD38XovFOnu7g%3D 12438441 Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 110(10):1429–1439. doi: 10.1172/JCI15777
57. 57. S Azeredo da Silveira BL Schneider C Cifuentes-Diaz D Sage T Abbas-Terki T Iwatsubo M Unser P Aebischer 2009 Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson’s disease Hum Mol Genet 18 5 872 887 10.1093/hmg/ddn417 1:CAS:528:DC%2BD1MXhvV2jtL4%3D 19074459 Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, Unser M, Aebischer P (2009) Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson’s disease. Hum Mol Genet 18(5):872–887. doi: 10.1093/hmg/ddn417
58. 58. KA Malkus E Tsika H Ischiropoulos 2009 Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson’s disease: how neurons are lost in the Bermuda triangle Mol Neurodegener 4 24 10.1186/1750-1326-4-24 10.1186/1750-1326-4-24 19500376 Malkus KA, Tsika E, Ischiropoulos H (2009) Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson’s disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener 4:24. doi: 10.1186/1750-1326-4-24
59. 59. K Ditaranto TL Tekirian AJ Yang 2001 Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer’s disease Neurobiol Dis 8 1 19 31 10.1006/nbdi.2000.0364 10.1006/nbdi.2000.0364 1:CAS:528:DC%2BD3MXpvVSqsw%3D%3D 11162237 Ditaranto K, Tekirian TL, Yang AJ (2001) Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer’s disease. Neurobiol Dis 8(1):19–31. doi: 10.1006/nbdi.2000.0364
60. 60. VN Uversky G Yamin PO Souillac J Goers CB Glaser AL Fink 2002 Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro FEBS Lett 517 1–3 239 244 10.1016/S0014-5793(02)02638-8 1:CAS:528:DC%2BD38XjtVals7w%3D 12062445 Uversky VN, Yamin G, Souillac PO, Goers J, Glaser CB, Fink AL (2002) Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett 517(1–3):239–244
61. 61. G Yamin CB Glaser VN Uversky AL Fink 2003 Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein J Biol Chem 278 30 27630 27635 10.1074/jbc.M303302200 10.1074/jbc.M303302200 1:CAS:528:DC%2BD3sXlsFKkt7w%3D 12754258 Yamin G, Glaser CB, Uversky VN, Fink AL (2003) Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem 278(30):27630–27635. doi: 10.1074/jbc.M303302200
62. 62. VN Uversky G Yamin LA Munishkina MA Karymov IS Millett S Doniach YL Lyubchenko AL Fink 2005 Effects of nitration on the structure and aggregation of alpha-synuclein Brain Res Mol Brain Res 134 1 84 102 10.1016/j.molbrainres.2004.11.014 10.1016/j.molbrainres.2004.11.014 1:CAS:528:DC%2BD2MXisFGmu7g%3D 15790533 Uversky VN, Yamin G, Munishkina LA, Karymov MA, Millett IS, Doniach S, Lyubchenko YL, Fink AL (2005) Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res Mol Brain Res 134(1):84–102. doi: 10.1016/j.molbrainres.2004.11.014
63. 63. JM Souza BI Giasson Q Chen VM Lee H Ischiropoulos 2000 Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies J Biol Chem 275 24 18344 18349 10.1074/jbc.M000206200 10.1074/jbc.M000206200 1:CAS:528:DC%2BD3cXktlymurc%3D 10747881 Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275(24):18344–18349. doi: 10.1074/jbc.M000206200
64. 64. R Hodara EH Norris BI Giasson AJ Mishizen-Eberz DR Lynch VM Lee H Ischiropoulos 2004 Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation J Biol Chem 279 46 47746 47753 10.1074/jbc.M408906200 10.1074/jbc.M408906200 1:CAS:528:DC%2BD2cXptl2gu7c%3D 15364911 Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, Ischiropoulos H (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 279(46):47746–47753. doi: 10.1074/jbc.M408906200
65. 65. K Uchida K Sakai K Itakura T Osawa S Toyokuni 1997 Protein modification by lipid peroxidation products: formation of malondialdehyde-derived N(epsilon)-(2-propenol)lysine in proteins Arch Biochem Biophys 346 1 45 52 10.1006/abbi.1997.0266 1:CAS:528:DyaK2sXmsVajtbo%3D 9328283 Uchida K, Sakai K, Itakura K, Osawa T, Toyokuni S (1997) Protein modification by lipid peroxidation products: formation of malondialdehyde-derived N(epsilon)-(2-propenol)lysine in proteins. Arch Biochem Biophys 346(1):45–52
66. 66. H Vicente Miranda TF Outeiro 2010 The sour side of neurodegenerative disorders: the effects of protein glycation J Pathol 221 1 13 25 10.1002/path.2682 10.1002/path.2682 20186922 Vicente Miranda H, Outeiro TF (2010) The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol 221(1):13–25. doi: 10.1002/path.2682
67. 67. V Padmaraju JJ Bhaskar UJ Prasada Rao PV Salimath KS Rao 2011 Role of advanced glycation on aggregation and DNA binding properties of alpha-synuclein J Alzheimers Dis 24 Suppl 2 211 221 10.3233/JAD-2011-101965 1:CAS:528:DC%2BC3MXltFGrsbY%3D 21441659 Padmaraju V, Bhaskar JJ, Prasada Rao UJ, Salimath PV, Rao KS (2011) Role of advanced glycation on aggregation and DNA binding properties of alpha-synuclein. J Alzheimers Dis 24(Suppl 2):211–221. doi: 10.3233/JAD-2011-101965
68. 68. A Kurz N Rabbani M Walter M Bonin P Thornalley G Auburger S Gispert 2011 Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress Cell Mol Life Sci 68 4 721 733 10.1007/s00018-010-0483-7 10.1007/s00018-010-0483-7 1:CAS:528:DC%2BC3MXhtFKrs74%3D 20711648 Kurz A, Rabbani N, Walter M, Bonin M, Thornalley P, Auburger G, Gispert S (2011) Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell Mol Life Sci 68(4):721–733. doi: 10.1007/s00018-010-0483-7
69. 69. A Negre-Salvayre R Salvayre N Auge R Pamplona M Portero-Otin 2009 Hyperglycemia and glycation in diabetic complications Antioxid Redox Signal 11 12 3071 3109 10.1089/ARS.2009.2484 10.1089/ars.2009.2484 1:CAS:528:DC%2BD1MXhsVGlt7jE 19489690 Negre-Salvayre A, Salvayre R, Auge N, Pamplona R, Portero-Otin M (2009) Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 11(12):3071–3109. doi: 10.1089/ARS.2009.2484
70. 70. LH Coker LE Wagenknecht 2011 Advanced glycation end products, diabetes, and the brain Neurology 77 14 1326 1327 10.1212/WNL.0b013e318231532b 10.1212/WNL.0b013e318231532b 21900634 Coker LH, Wagenknecht LE (2011) Advanced glycation end products, diabetes, and the brain. Neurology 77(14):1326–1327. doi: 10.1212/WNL.0b013e318231532b
71. 71. S Yamagishi 2011 Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes Exp Gerontol 46 4 217 224 10.1016/j.exger.2010.11.007 10.1016/j.exger.2010.11.007 1:CAS:528:DC%2BC3MXjs1Sltbc%3D 21111800 Yamagishi S (2011) Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 46(4):217–224. doi: 10.1016/j.exger.2010.11.007
72. 72. RB Nawale VK Mourya SB Bhise 2006 Non-enzymatic glycation of proteins: a cause for complications in diabetes Indian J Biochem Biophys 43 6 337 344 1:CAS:528:DC%2BD2sXhtFCltrc%3D 17285797 Nawale RB, Mourya VK, Bhise SB (2006) Non-enzymatic glycation of proteins: a cause for complications in diabetes. Indian J Biochem Biophys 43(6):337–344
73. 73. S Shaikh LF Nicholson 2008 Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation J Neurosci Res 86 9 2071 2082 10.1002/jnr.21644 10.1002/jnr.21644 1:CAS:528:DC%2BD1cXoslyhsLY%3D 18335520 Shaikh S, Nicholson LF (2008) Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 86(9):2071–2082. doi: 10.1002/jnr.21644
74. 74. PJ Thornalley A Langborg HS Minhas 1999 Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose Biochem J 344 Pt 1 109 116 10.1042/0264-6021:3440109 1:CAS:528:DyaK1MXns1yjtrY%3D 10548540 Thornalley PJ, Langborg A, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344(Pt 1):109–116
75. 75. JP Richard 1993 Mechanism for the formation of methylglyoxal from triosephosphates Biochem Soc Trans 21 2 549 553 1:CAS:528:DyaK3sXkt1ehtrc%3D 8359530 Richard JP (1993) Mechanism for the formation of methylglyoxal from triosephosphates. Biochem Soc Trans 21(2):549–553
76. 76. JD McPherson BH Shilton DJ Walton 1988 Role of fructose in glycation and cross-linking of proteins Biochemistry 27 6 1901 1907 10.1021/bi00406a016 1:CAS:528:DyaL1cXht1Kqurs%3D 3132203 McPherson JD, Shilton BH, Walton DJ (1988) Role of fructose in glycation and cross-linking of proteins. Biochemistry 27(6):1901–1907
77. 77. MA Grillo S Colombatto 2008 Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases Amino Acids 35 1 29 36 10.1007/s00726-007-0606-0 10.1007/s00726-007-0606-0 1:CAS:528:DC%2BD1cXmslWjsbg%3D 18008028 Grillo MA, Colombatto S (2008) Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids 35(1):29–36. doi: 10.1007/s00726-007-0606-0
78. 78. H Choei N Sasaki M Takeuchi T Yoshida W Ukai S Yamagishi S Kikuchi T Saito 2004 Glyceraldehyde-derived advanced glycation end products in Alzheimer’s disease Acta Neuropathol 108 3 189 193 10.1007/s00401-004-0871-x 10.1007/s00401-004-0871-x 1:CAS:528:DC%2BD2cXmt1Krtbc%3D 15221334 Choei H, Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yamagishi S, Kikuchi S, Saito T (2004) Glyceraldehyde-derived advanced glycation end products in Alzheimer’s disease. Acta Neuropathol 108(3):189–193. doi: 10.1007/s00401-004-0871-x
79. 79. H Shimura MG Schlossmacher N Hattori MP Frosch A Trockenbacher R Schneider Y Mizuno KS Kosik DJ Selkoe 2001 Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease Science 293 5528 263 269 10.1126/science.1060627 10.1126/science.1060627 1:CAS:528:DC%2BD3MXlt1yitL4%3D 11431533 Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 293(5528):263–269. doi: 10.1126/science.1060627
80. 80. RN Cole GW Hart 2001 Cytosolic O-glycosylation is abundant in nerve terminals J Neurochem 79 5 1080 1089 10.1046/j.1471-4159.2001.00655.x 1:CAS:528:DC%2BD3MXptFOhtro%3D 11739622 Cole RN, Hart GW (2001) Cytosolic O-glycosylation is abundant in nerve terminals. J Neurochem 79(5):1080–1089
81. 81. MM Tompkins WP Gai S Douglas SJ Bunn 2003 Alpha-synuclein expression localizes to the Golgi apparatus in bovine adrenal medullary chromaffin cells Brain Res 984 1–2 233 236 10.1016/S0006-8993(03)03040-3 1:CAS:528:DC%2BD3sXmsVKgurg%3D 12932858 Tompkins MM, Gai WP, Douglas S, Bunn SJ (2003) Alpha-synuclein expression localizes to the Golgi apparatus in bovine adrenal medullary chromaffin cells. Brain Res 984(1–2):233–236
82. 82. S Pashikanti GA Boissonneault D Cervantes-Laurean 2011 Ex vivo detection of histone H1 modified with advanced glycation end products Free Radic Biol Med 50 10 1410 1416 10.1016/j.freeradbiomed.2011.01.034 10.1016/j.freeradbiomed.2011.01.034 1:CAS:528:DC%2BC3MXltFyktb4%3D 21315148 Pashikanti S, Boissonneault GA, Cervantes-Laurean D (2011) Ex vivo detection of histone H1 modified with advanced glycation end products. Free Radic Biol Med 50(10):1410–1416. doi: 10.1016/j.freeradbiomed.2011.01.034
83. 83. L Chen Y Wei X Wang R He 2010 Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products PLoS One 5 2 e9052 10.1371/journal.pone.0009052 10.1371/journal.pone.0009052 20140223 Chen L, Wei Y, Wang X, He R (2010) Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 5(2):e9052. doi: 10.1371/journal.pone.0009052
84. 84. M Takeuchi S Yamagishi 2004 TAGE (toxic AGEs) hypothesis in various chronic diseases Med Hypotheses 63 3 449 452 10.1016/j.mehy.2004.02.042 10.1016/j.mehy.2004.02.042 1:CAS:528:DC%2BD2cXmt1Churg%3D 15288366 Takeuchi M, Yamagishi S (2004) TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses 63(3):449–452. doi: 10.1016/j.mehy.2004.02.042
85. 85. K Jomova D Vondrakova M Lawson M Valko 2010 Metals, oxidative stress and neurodegenerative disorders Mol Cell Biochem 345 1–2 91 104 10.1007/s11010-010-0563-x 10.1007/s11010-010-0563-x 1:CAS:528:DC%2BC3cXhtlOrurzM 20730621 Jomova K, Vondrakova D, Lawson M, Valko M (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345(1–2):91–104. doi: 10.1007/s11010-010-0563-x
86. 86. Munch G, Westcott B, Menini T, Gugliucci A (2010) Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids. doi: 10.1007/s00726-010-0777-y
87. 87. MD Ledesma P Bonay C Colaco J Avila 1994 Analysis of microtubule-associated protein tau glycation in paired helical filaments J Biol Chem 269 34 21614 21619 1:CAS:528:DyaK2cXlsFCrsr4%3D 8063802 Ledesma MD, Bonay P, Colaco C, Avila J (1994) Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 269(34):21614–21619
88. 88. MA Smith G Perry 1994 Alzheimer disease: an imbalance of proteolytic regulation? Med Hypotheses 42 4 277 279 10.1016/0306-9877(94)90132-5 1:STN:280:DyaK2czlt1amsg%3D%3D 8072436 Smith MA, Perry G (1994) Alzheimer disease: an imbalance of proteolytic regulation? Med Hypotheses 42(4):277–279
89. 89. YG Choi S Lim 2010 N(Varepsilon)-(carboxymethyl)lysine linkage to alpha-synuclein and involvement of advanced glycation end products in alpha-synuclein deposits in an MPTP-intoxicated mouse model Biochimie 92 10 1379 1386 10.1016/j.biochi.2010.06.025 10.1016/j.biochi.2010.06.025 1:CAS:528:DC%2BC3cXht1ClsrrI 20624443 Choi YG, Lim S (2010) N(Varepsilon)-(carboxymethyl)lysine linkage to alpha-synuclein and involvement of advanced glycation end products in alpha-synuclein deposits in an MPTP-intoxicated mouse model. Biochimie 92(10):1379–1386. doi: 10.1016/j.biochi.2010.06.025
90. 90. G Munch HJ Luth A Wong T Arendt E Hirsch R Ravid P Riederer 2000 Crosslinking of alpha-synuclein by advanced glycation endproducts—an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20 3–4 253 257 10.1016/S0891-0618(00)00096-X 1:CAS:528:DC%2BD3MXht1Oqtrc%3D 11207423 Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P (2000) Crosslinking of alpha-synuclein by advanced glycation endproducts—an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20(3–4):253–257
91. 91. D Lee CW Park SR Paik KY Choi 2009 The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process Biochim Biophys Acta 1794 3 421 430 10.1016/j.bbapap. 2008.11.016 10.1016/j.bbapap.2008.11.016 1:CAS:528:DC%2BD1MXhsFOlsb0%3D 19103312 Lee D, Park CW, Paik SR, Choi KY (2009) The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process. Biochim Biophys Acta 1794(3):421–430. doi: 10.1016/j.bbapap.2008.11.016
92. 92. E Dalfo M Portero-Otin V Ayala A Martinez R Pamplona I Ferrer 2005 Evidence of oxidative stress in the neocortex in incidental Lewy body disease J Neuropathol Exp Neurol 64 9 816 830 10.1097/01.jnen.0000179050.54522.5a 1:CAS:528:DC%2BD2MXhtlSjs73P 16141792 Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64(9):816–830